GLP1R and cancer: Lin et al had addressed a phenomenon regarding the different cancer risk profiles related to individual GLP-1 receptor agonists in their review article[15], which might reflect the hypothesis of “biased agonism and polymorphic variation” regarding the different activation of downstream signal transduction pathways in response to different extrinsic GLP-1 receptor agonists[16].